C. C. Abbott
Contributor since: 2017
Latest Articles
Tonix: Searching For Efficacy In PTSD
Protalix: BRIDGE's Preliminary Data Raises More Questions Than It Answers
Tonix Is A Buy For Potentially Great Return On PTSD Breakthrough, Part 2
ContraFect: A Buy For Their Next Generation Anti-Infection Proteins
A 3-Way Race To The Next Generation IPF Drug: Galapagos, FibroGen, Prometic
Pfenex: A Buy For Their Therapeutic Proteins Platform
How De-Risked Is Protalix's Fabry Superiority Trial?
Tonix Is A Buy For Potentially Great Return On PTSD Breakthrough
The Market Has Spoken: Buy Sarepta
SIGA Technologies: A Buy For The Smallpox Treatment
Asterias Biotherapeutic: Spinal Injury Stem Cell Therapy Play
Prometic: Still A Buy Despite The Delay In Plasminogen's BLA
Antibe: A Buy For Their GI-Safe Next-Generation NSAID Potential
Protalix: A Definite Sell - No Prize For The Fourth Runner Up
Protalix: It's Time To Sell
Summit Therapeutics: A Buy For Its DMD Drug
Rigel Is A Buy For Its First NDA
How To Verify A Buy Or Sell Rating Objectively
Corbus Is A Buy, But Not For Cystic Fibrosis
Axovant: Why I Won't Be An Investor At Any Level
Protalix: A Rooted Biotech For The Patient And The Brave
Capricor: Risks Outweigh 'HOPE'
Capricor May Offer 'HOPE' To DMD Patients
Catabasis And Capricor: 2 Solid Buys In DMD Treatment
Prometic: A Rebuttal To Bloom Burton & Co.'s Analyst Report
The Countdown Has Begun For Prometic's Ryplazim
Rigel Pharmaceutical: An Update
Axovant Sciences: A Buy At A Bargain Price
Tonix's Tonmya Treats PTSD By Helping Sufferers Sleep Better
TSO3 Inc.: Taking The Fight To The Superbugs
Pluristem Therapeutics Inc.: A Biotech Company Inspired By Life
Compare 4 Companies' Cystic Fibrosis Drugs: Roche, Protalix, Vertex And Galapagos